Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992–2012

Irene Slavc¹, Monika Chocholous¹, Ulrike Leiss¹, Christine Haberler², Andreas Peyrl¹, Amedeo A. Azizi¹, Karin Dieckmann³, Adelheid Woehrer², Christina Peters⁴, Georg Widhalm⁵, Christian Dorfer⁵ & Thomas Czech⁵

¹Department of Pediatrics, Medical University of Vienna, Vienna, Austria
²Institute of Neurology, Medical University of Vienna, Vienna, Austria
³Department of Radiotherapy, Medical University of Vienna, Vienna, Austria
⁴SCT Unit, St. Anna Kinderspitäl, Vienna, Austria
⁵Department of Neurosurgery, Medical University of Vienna, Vienna, Austria

Keywords
ATRT, delayed local radiotherapy, high-dose chemotherapy, improved survival, multimodal therapy

Abstract
Atypical teratoid rhabdoid tumors (ATRTs) are recently defined highly aggressive embryonal central nervous system tumors with a poor prognosis and no definitive guidelines for treatment. We report on the importance of an initial correct diagnosis and disease-specific therapy on outcome in 22 consecutive patients and propose a new treatment strategy. From 1992 to 2012, nine patients initially diagnosed correctly as ATRT (cohort A, median age 24 months) were treated according to an intensive multimodal regimen (MUV-ATRT) consisting of three 9-week courses of a dose-dense regimen including doxorubicin, cyclophosphamide, vincristine, ifosfamide, cisplatin, etoposide, and methotrexate augmented with intrathecal therapy, followed by high-dose chemotherapy (HDCT) and completed with local radiotherapy. As of July 2013, 5-year overall survival (OS) and event-free survival (EFS) for all 22 consecutive patients was 56.3/C611.3% and 52.9/C611.0%, respectively. For MUV-ATRT regimen-treated patients (cohort A) 5-year OS was 100% and EFS was C610.5%. For patients treated differently (cohort B) 5-year OS and EFS were 28.8/C613.1%. All nine MUV-ATRT regimen-treated patients are alive for a median of 76 months (range: 16–197), eight in first complete remission. Our results compare favorably to previously published data. The drug combination and sequence used in the proposed MUV-ATRT regimen appear to be efficacious in preventing early relapses also in young children with M1–M3 stage disease allowing postponement of radiotherapy until after HDCT.

Introduction
Atypical teratoid rhabdoid tumors (ATRTs) are rare, highly aggressive embryonal central nervous system (CNS) tumors primarily encountered in children with a peak incidence in infants less than 3 years of age [1]. Rhabdoid tumors were originally described as an aggressive variant of Wilms tumors with rhabdomyosarcomatous features and subsequently observed also in soft tissues and the CNS [2]. ATRTs were defined as an entity in 1996 [3] and added to the World Health Organization (WHO) brain tumor classification in 2000 [4]. Histopathologically, ATRTs are characterized by rhabdoid tumor cells and varying amounts of small undifferentiated primitive neuroectodermal tumor (PNET)-like, mesenchymally, and/or epithelially differentiated tumor cells. The vast majority of
ATRTs are characterized by alterations of the SMARCB1 (hSNF5/INI1) gene at chromosomal locus 22q11.23, resulting in loss of nuclear protein expression. Consistent with the role of a tumor suppressor gene, biallelic inactivation of SMARCB1 is present in rhabdoid tumors, and ATRTs may occur sporadically or in the setting of a rhabdoid predisposition syndrome [5, 6].

Before the introduction of an antibody directed against the SMARCB1/INI1 protein into routine diagnostics in 2004 [7], ATRTs were frequently misdiagnosed if characteristic rhabdoid tumor cells were missing in the biopsy specimen [8]. The most frequent misdiagnosis of ATRT was medulloblastoma or CNS PNET, particularly when a primitive neuroepithelial component was prominent [1, 9].

Historically, the prognosis of patients with ATRT was poor with a median survival of approximately 1 year [10–16]. Due to the rarity of the disease and the lack of large formal prospective trials, the patients were usually treated in a heterogeneous manner, and no definitive guidelines for optimal treatment have been established. More recently, long-term survivors including patients with recurrent and disseminated disease have been reported, and disease-specific protocols and registries combining maximal surgical resection, intensive chemotherapy with or without stem cell support, and radiotherapy have been opened and showed encouraging, albeit preliminary results [17–19].

We report on the importance of an initial correct diagnosis and consequently disease-specific therapy on outcome in 22 consecutive patients with ATRT, treated at the Medical University of Vienna between 1992 and 2012, and propose a new treatment strategy. 

**Patients and Methods**

A retrospective analysis applying the SMARCB1/INI1 antibody to all highly malignant pediatric brain tumors treated at the Medical University of Vienna (MUV) since 1992 disclosed 22 patients with ATRT. The clinical characteristics of the patients are shown in Table 1.

Nine of the patients originally diagnosed correctly (cohort A) were treated uniformly according to the same prospective strategy used in a first index patient diagnosed in 1997 who had become a long-term survivor. Thirteen patients were treated differently (cohort B), most of whom according to protocols for their respective diagnoses.

**Age at diagnosis and gender**

Median age at diagnosis was 24 months (range: 9 months–17 years) in cohort A and 30 months (range: 2 months–22 years) in cohort B. The male:female ratio was 1.8:1 for all patients.

Tumor location, staging, and degree of surgical resection are shown in Table 1. Fifteen patients received an Ommaya reservoir, in one of these patients, who was shunt-dependent, Ommaya reservoir placement was combined with exchanging the shunt to a valve with an integrated on-off device [20].

**Histopathology**

For histopathology review, conventional histological stainings and the immunohistochemical analysis of SMARCB1 protein expression were performed as previously described [8]. According to the current WHO classification of tumors of the CNS [21] ATRT was diagnosed when rhabdoid tumor cells were present and/or divergent differentiation along epithelial, mesenchymal, neuronal, or glial lines were found, and when complete loss of SMARCB1 protein expression was observed in tumor cell nuclei, but expression was retained in preexisting cells (e.g., endothelial cells).

**Chemotherapy**

Following surgery all but one patient, who died shortly after surgery, received further antitumor therapy. For patients with an initial correct diagnosis, a multimodal treatment strategy which was successful in a first index patient became the standard of treatment for all except two consecutive cases since 2002. The proposed treatment strategy (MUV-ATRT regimen) consisted of three 9-week courses of a dose-dense regimen including doxorubicin, cyclophosphamide, vincristine, ifosfamide, cisplatin, etoposide, and high-dose methotrexate (HD-MTX), augmented with intrathecal therapy and followed by high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell reinfusion according to a modified Finlay protocol (cyclophosphamide, etoposide 250 mg/m², and thiotepa 300 mg/m² given simultaneously from Day 6 to Day 4) [22]. Treatment was completed with local radiotherapy starting 6 weeks after HDCT (Fig. 1A and B). The two exceptions were a 14-year-old patient (case 11, cohort B) who moved to another country and an 11-year-old patient (case 13, cohort B) who was operated in another hospital and was switched to craniospinal irradiation following major postoperative infectious complications and poor bone marrow tolerance.

Most patients in cohort B were treated according to the HIT brain tumor protocols proposed by the German Society for Paediatric Oncology and Haematology (GPOH) and in use for their respective diagnoses at the time, that is, HIT SKK 92 [23] and HIT 91 [24].
### Table 1. Patient characteristics, type of therapy, and outcome.

| Case | Age at DX (months/years), gender | Year of DX | Primary tumor location | Chang stage | Extent of resection | Original DX | SMARC B1 | Chemotherapy | Intrathecal chemotherapy | HDCT | Radiotherapy | Response to CT | Time to relapse/progress (months) | Duration of survival (months) | Disease status |
|------|----------------------------------|-----------|-----------------------|-------------|---------------------|-------------|-----------|-------------|-------------------------|------|-------------|----------------|-----------------------------|-----------------------------|---------------|
| Cohort A |                                |           |                       |             |                     |             |           |             |                         |      |             |                |                             |                             |               |
| 1    | 6 years F                         | 1997      | Frontal               | M0          | STR                 | ATRT        | Neg.      | MUV-ATRT   | –                       | +   | Focal       | CR              | –                     | 197            | NED           |
| 2    | 24 months M                       | 2002      | Post. fossa           | M0          | GTR                 | ATRT        | Neg.      | MUV-ATRT   | Double                  | +   | Focal       | n.e.            | –                     | 132            | NED           |
| 3    | 12 months M                       | 2002      | Post. fossa           | M0          | GTR                 | ATRT        | Neg.      | MUV-ATRT   | Double                  | +   | Focal       | n.e.            | (114)†          | 127            | NED           |
| 4    | 9 months F                        | 2005      | Post. fossa           | M3          | PR                  | ATRT        | Neg.      | MUV-ATRT   | Triple                   | +   | Focal       | CR              | –                     | 98             | NED           |
| 5    | 23 months M                       | 2007      | Post. fossa           | M1          | STR                 | ATRT        | Neg.      | MUV-ATRT   | Triple                   | +   | Focal       | PR              | –                     | 76             | NED           |
| 6    | 20 months M                       | 2009      | Post. fossa           | M1          | GTR                 | ATRT        | Neg.      | MUV-ATRT   | Triple                   | +   | Focal       | CR              | –                     | 53             | NED           |
| 7    | 56 months M                       | 2009      | 3rd ventr.            | M1          | GTR                 | ATRT        | Neg.      | MUV-ATRT   | Double                  | +   | Focal       | CR              | 16                     | 48             | NED           |
| 8    | 17 years F                        | 2009      | Temporal              | M0          | STR                 | ATRT        | Neg.      | MUV-ATRT   | Double                  | +   | Focal       | CR              | –                     | 44             | NED           |
| 9    | 13 years M                        | 2012      | Thalamus              | M0          | GTR                 | ATRT        | Neg.      | MUV-ATRT   | Double                  | +   | Focal       | n.e.            | –                     | 16             | NED           |
| Cohort B |                                |           |                       |             |                     |             |           |             |                         |      |             |                |                             |                             |               |
| 1    | 7 months F                        | 1992      | Post. fossa           | M0          | GTR                 | EPB         | Neg.      | HIT-SKK-92 | MTX                     | –   | No          | PD              | 3                      | 8              | DOD           |
| 2    | 2 months M                        | 1993      | Post. fossa           | M0          | GTR                 | MB          | Neg.      | HIT-SKK-92 | MTX                     | –   | No          | n.e.            | –                     | 0              | DOD           |
| 3    | 20 months M                       | 1993      | Post. fossa           | M0          | STR                 | MB          | Neg.      | HIT-SKK-92 | MTX                     | –   | No          | PR              | 6                      | 8              | DOD           |
| 4    | 9 months F                        | 1994      | Basal ganglia         | n.a.        | PR                  | PNET        | Neg.      | HIT-91     | Mafo                    | CSI + GKN | CR          | (174)†          | 200                      | DOC           |
| 5    | 2 months M                        | 1998      | Post. fossa           | M3          | STR                 | MB          | Neg.      | HIT-SKK-92 | MTX                     | –   | No          | PD              | 3                      | 5              | DOD           |
| 6    | 4 months M                        | 1998      | Post. fossa           | M3          | GTR                 | EPB         | Neg.      | HIT-SKK-92 | MTX                     | –   | No          | PD              | 3                      | 7              | DOD           |
| 7    | 39 months M                       | 1999      | Spinal                | M0          | Biopsy              | ATRT        | Neg.      | 4 × PEI    | –                       | +   | Focal       | CR              | 18                     | 24             | DOD           |
| 8    | 30 months M                       | 1999      | Spinal                | M1          | Biopsy              | EWS         | Neg.      | 4 × PEI    | –                       | –   | Focal       | PR              | 4                      | 6              | DOD           |
| 9    | 14 months F                       | 1998      | Pineal/midbrain       | M0          | GTR                 | PNET        | Neg.      | HIT-SKK-92 | MTX                     | +   | No          | n.e.            | 46                     | 56             | DOD           |
| 10   | 35 months M                       | 2005      | Thalamus              | n.a.        | PR                  | GBM         | Neg.      | 8 × PEI    | –                       | –   | Focal       | CR              | –                     | 100            | NED           |
| 11   | 14 years F                        | 2006      | Frontal               | n.a.        | STR                  | ATRT        | Neg.      | n.a.†      | –                       | –   | CS†         | n.e.            | –                     | 7              | DOC           |
| 12   | 22 years M                        | 2007      | Frontal               | M0          | GTR                 | PNET        | Neg.      | HIT-2000   | –                       | –   | CS†         | n.e.            | –                     | 74             | NED           |
| 13   | 11 years F                        | 2010      | Fronto-par.           | M0          | STR                  | ATRT        | Neg.      | MUV-ATRT†  | Double                  | –   | CS†         | SD              | –                     | 34             | SD            |

DX, diagnosis; HDCT, high-dosage chemotherapy; CT, chemotherapy; F, female; M, male; n.e., not evaluable; post., posterior; ventr., ventricle; n.a., not available; STR, subtotal resection; GTR, gross total resection; PR, partial resection/partial remission; MUV-ATRT, Medical University of Vienna ATRT-protocol; MTX, methotrexate; Mafo, mafosfamide; CSI, craniospinal irradiation; GKN, gamma knife; CR, complete remission; PD, progressive disease; NED, no evidence of disease; DOD, dead of disease; DOC, death of other cause; AWD, alive with disease; EPB, ependymoblastoma; MB, medulloblastoma; ATRT, atypical teratoid rhabdoid tumor; PNET, CNS primitive neuroectodermal tumor; EWS, Ewing sarcoma; GBM, glioblastoma multiforme.

1Secondary malignancy.

2Patient moved to another country.

3Intention-to-treat (changed to CSI because of delay in CT following septicemia).
**Intrathecal chemotherapy**

Intraventricular therapy was administered to eight patients of cohort A and consisted of either alternating mafosfamide (15 mg) [25] and methotrexate (2 mg/day for 4 days) alternating methotrexate, liposomal cytarabine (25 mg for children ≤3 years, 35 mg for children >3 years) [26] and etoposide 0.25 mg (patients <1 year of age) – 0.5 mg daily for 5 days or alternating liposomal cytarabine and etoposide and varied over time because mafosfamide was no longer available (Fig. 1A and B). Patients treated according to HIT SKK 92 received intraventricular methotrexate only.

**Radiotherapy**

Local radiotherapy was applied based on a 3D-conformal treatment plan. Fraction sizes were 1.8 Gy for all target vol-

---

**Figure 1.** MUV-ATRT regimen for newly diagnosed ATRT patients. (A) Week 0–27. (B) Week 28–43 and cumulative doses. MUV-ATRT, Medical University of Vienna ATRT-protocol; ATRT, atypical teratoid rhabdoid tumor.
ume, with a total dose of 54 Gy in most patients. In cohort A, all patients independent of M-stage were treated with local radiotherapy only. The 9-month-old patient (case 4, cohort A) with a high tumor cell count in the cerebrospinal fluid (CSF) and a large spinal metastasis received local irradiation to the posterior fossa and to the lumbar metastasis. In this case, the total dose was limited to 43 Gy to the posterior fossa and 40.6 Gy to the lumbar metastasis.

In cohort B, four patients, 9, 11, 14, and 22 years old at diagnosis, received craniospinal irradiation. Three of five patients treated according to HIT SKK 92 recurred during chemotherapy and none was irradiated (Table 1).

Toxicity and response evaluation

The Common Terminology Criteria for Adverse Events (version 3.0) was used to grade toxicity of the MUV-ATRT regimen. Neuroimaging studies were performed every 6 weeks to 3 months and CSF was evaluated at each intrathecal chemotherapy. Responses were defined as previously described for standard radiographic criteria [27].

Statistical analysis

Statistical analyses were conducted according to the procedure of the SPSS 20.0 for Windows® package (IBM SPSS Statistics 20.0 für Win.XP/Vista/7, IBM Corporation). Besides descriptive methods, the Kaplan–Meier method was used to estimate the distributions of overall survival (OS) and event-free survival (EFS). Survival was measured from the time of diagnosis to the date of death or last follow-up. In estimating EFS, tumor recurrence, tumor progression, secondary malignancy or death from any cause, whichever developed first, were defined as events. Significance of differences between subgroups was calculated using the log-rank test. A Cox-regression analysis was performed to investigate the impact of the variables—radiotherapy, HDCT, and intrathecal therapy—on OS and EFS. For all tests \( P < 0.05 \) was considered significant.

Neuropsychometric assessment of patients treated according to the MUV-ATRT regimen

Neuropsychological data were available for all nine patients treated according to the MUV-ATRT regimen. Four patients were tested before start of chemotherapy and one before HDCT. For four patients, the first full assessment was only possible during follow-up, due to major developmental delay at diagnosis, language problems or very young age. All patients were retested at least once.

The neuropsychological test-battery included age-appropriate Wechsler Scale or a developmental test for patients younger than 3 years of age. In addition, the patients were assessed with age-appropriate tests for attention, memory, processing speed, and visual-spatial perception when possible.

Results

Histopathology

The tumors of 22 consecutive patients had characteristic histopathologic and immunohistochemical features and were SMARCB1/INI1 immunonegative. Twelve of these 22 ATRTs were initially diagnosed correctly, whereas 10 were detected retrospectively. Initial diagnoses of the originally misclassified tumors are shown in Table 1.

Response to treatment

Response was evaluable in a total of 15 patients from both cohorts including patients who had incomplete resection and/or M1–M3 disease. Response is shown in Table 1. Except for patients treated according to the MUV-ATRT regimen patients with residual tumor treated with repeated cycles of PEI (cisplatin 20 mg/m² for 5 days, ifosfamide 1500 mg/m² for 5 days, and etoposide 100 mg/m² for 3 days) chemotherapy achieved the best response suggesting that this combination is particularly effective in ATRTs. However, all three patients treated with PEI chemotherapy and local irradiation did not receive intrathecal therapy and two recurred with leptomeningeal disease without local relapse stressing the importance of intrathecal therapy in focally irradiated patients. In cohort A, all four patients with tumor cells in the CSF treated according to the MUV-ATRT regimen cleared their tumor cells from the CSF and only one patient recurred with leptomeningeal metastases outside of the irradiation field 16 months after diagnosis (Table 1). None of the 16 irradiated patients of both cohorts recurred within the irradiation field.

For the entire cohort of 22 patients the use of radiotherapy was significantly positive for both OS and EFS (\( P < 0.001 \) vs. \( P < 0.001 \)). Similarly, HDCT was associated with a significant positive prognostic value for both OS and EFS (\( P = 0.018 \) vs. \( P = 0.039 \)). Intrathecal chemotherapy had no significant influence on OS and EFS (\( P = 0.265 \) vs. \( P = 0.917 \)). Cox-regression analyses of these variables showed no significant influence on OS but identified radiotherapy as an independent positive prognostic factor for EFS (\( P = 0.002 \)).

Outcome

All nine MUV-ATRT regimen-treated patients are alive for a median of 76 months (range: 16–197), eight in first
CR, one patient who developed leptomeningeal metastases outside of the irradiation field 16 months after diagnosis is alive in second CR and off therapy for 12 months. Another patient (case 3) diagnosed with a histopathologically confirmed SMARCB1 nucleopositive glioblastoma within the irradiation field as secondary tumor 9.5 years after diagnosis of his ATRT is also alive.

In cohort B, three patients diagnosed at the age of 35 months, 9, and 22 years, respectively, became long-term survivors, and a fourth patient diagnosed at the age of 11 years has stable disease and is off therapy for 12 months. However, the 9-year-old patient developed a malignant peripheral nerve sheath tumor of the brachial plexus 14.5 years after diagnosis of her basal ganglia ATRT and succumbed to her secondary tumor 16.5 years after diagnosis of her original tumor. The 14-year-old who was treated according to a local protocol in another country died of treatment toxicity.

As of July 2013, 5-year OS for MUV-ATRT-treated patients is 100% and 5-year EFS 88.9 ± 10.5%, and for patients treated with other protocols (cohort B) both, 5-year OS and EFS, are 28.8 ± 13.1% (Fig. 2A and B).

Feasibility and toxicity of MUV-ATRT chemotherapy

Chemotherapy according to the MUV-ATRT regimen was generally well tolerated and only minor dose adjustments and delays occurred. The most frequent but not unexpected toxicity included bone marrow suppression after cyclophosphamide and vincristine. Great attention was directed toward avoiding febrile neutropenia with consecutive delays in treatment and preemptive IV antibiotics were given during neutropenia. There was one grade 4 mucositis and one grade 3 liver enzyme elevation after methotrexate. Sufficient stem cell harvest was feasible after chemotherapy and cytokine stimulation with G-CSF in all patients. Hematopoietic reconstitution was fast and no graft failure occurred. Following HDCT there was one grade 4 and one grade 3 mucositis, one grade 4 and one grade 3 dermatitis, and one grade 3 liver enzyme elevation. Two patients with cerebellar pontine angle tumors were deaf on one ear (cases 4 and 5) at the time of diagnosis. Five patients developed grade 3 hearing loss (<4 kHz >20 dB) according to the Muenster classification [28] requiring hearing aids, and one patient (case 4) a grade 4 hearing loss (<4 kHz of at least 80 dB) requiring a cochlea implant.

Focal radiotherapy was started no earlier than 6 weeks after HDCT. No problems such as radiation recall, brain edema or necrosis occurred.

Neuropsychological test results of MUV-ATRT-treated patients

Full IQ scale or total developmental score in nine patients treated according to the MUV-ATRT regimen showed mixed results with four patients scoring within their age norm (mean ± 1 SD; i.e. between 16th and 84th percentile) at all evaluation times (cases 1, 5, 6, and 7). One
patient (case 4) improved over time, finally showing age-appropriate results. Four patients scored below age norm (cases 2, 3, 8, and 9) at all evaluation times including one patient (case 2) originally admitted to the pediatric neurology division for evaluation of psychomotor retardation, and two patients (cases 8 and 9) had already attended schools with special educational service prior to diagnosis. Nevertheless, cases 2 and 3 are currently able to attend regular elementary school with special educational service.

**Discussion**

While substantial progress has been made in understanding the biology of ATRT, the optimal chemotherapy regimen has yet to be determined, and data supporting a particular combination of agents are lacking. Despite often impressive responses to chemotherapy, the majority of patients in all published studies developed progressive disease early, within 24 weeks of diagnosis, suggesting a rapid development of resistance in ATRTs [15, 16, 18]. The 5-year OS of 56.3 ± 11.3% and EFS of 52.9 ± 11.0% for the whole cohort of 22 consecutive patients treated at our institution compare favorably to all previously published data and seem to have been achieved by the introduction of a prospective uniform treatment protocol (MUV-ATRT regimen), which attained a 5-year OS of 100% and 5-year EFS of 88.9 ± 10.58% in nine patients with an initial correct diagnosis of ATRT.

The role of age at diagnosis has previously been reported important in predicting prognosis [10, 12, 15]. Although the median age of patients treated according to the MUV-ATRT regimen of 24 months was slightly higher than in some other reports, all five patients ≤24 months became long-term survivors and remained in CR from their disease. In most reports, long-term survival in the younger patient cohort was only achieved with early radiotherapy, stressing the importance for this modality also in the younger age group [13, 29, 30]. However, this potentially life-saving treatment option comes at the cost of serious long-term sequelae such as cognitive, motor, visual, and hearing impairment [23, 31–33].

In contrast to the published data highlighting the importance of early upfront radiotherapy [13, 18, 29], our experience with the MUV-ATRT regimen shows that local radiotherapy may be safely postponed for 9 months and deferred to the end of therapy between weeks 38 and 43. All nine patients achieved and/or maintained CR throughout their whole treatment and only one patient recurred with metastases outside of the irradiation field 16 months after diagnosis. It is notable that three patients had M1 stage disease at diagnosis and one 9-month-old had massive tumor cells in the CSF and a spinal metastasis. All four patients with M1–M3 stage tumors were treated with local irradiation only, albeit the latter to both sites with residues suggesting that the combination of intrathecal therapy and systemic HD-MTX, which shows good penetration into the CSF, is efficacious in eradicating ATRT tumor cells in the CSF. No radiation recall or transverse myelitis as described for three patients treated with a protocol based on a regimen for children with rhabdomyosarcoma with parameningeal extension [18] was observed in any of our patients.

As to the sequence and combination of drugs in our MUV-ATRT regimen, doxorubicin, which was introduced into the multiagent combination based on prior case reports suggesting efficacy [17], was started at a median of 11 days postoperatively (range: 5–28 days). As doxorubicin monotherapy at the proposed dose is not myelosuppressive it does not preclude additional surgery for third ventriculostomy, Ommaya reservoir or shunt placement. The second cycle consisting of cyclophosphamide and vincristine, while myelosuppressive, is usually well tolerated if infection is prevented. Regarding PEI or ICE-type chemotherapy several previous reports suggested that a combination of cisplatin, ifosfamide, and etoposide is efficacious in patients with ATRTs [11, 34]. This is in accordance with our own observation. Three patients of cohort B receiving PEI chemotherapy courses had a dramatic response to this combination. The only long-term survivor of cohort B diagnosed under the age of 3 years had a partially resected thalamic tumor and achieved complete remission with eight cycles of PEI chemotherapy and focal irradiation. Another patient (case 7 of cohort B) with a spinal ATRT, who had biopsy only and was treated with four cycles of PEI followed by HDCT and irradiation, had a complete response to PEI therapy. He did not receive intrathecal therapy and recurred with metastases without local relapse 18 months after diagnosis, and parents elected to forgo relapse therapy. In retrospect, except for thiopeta during HDCT none of the drugs administered systemically had the potential to penetrate into the CSF and reach cytoidal levels necessary to kill tumor cells floating in the CSF. Similarly, case 8 of cohort B with spinal ATRT, admitted paraplegic and misdiagnosed as Ewing sarcoma, showed a very good partial response by MRI to PEI chemotherapy, and recovered from all neurologic deficits before developing progressive leptomeningeal disease during local irradiation.

HD MTX also used in “Head Start II” [35] appears to be efficacious in ATRT and was well tolerated when given twice in a weekly interval by all young children, and no leukoencephalopathy as evidenced by MRI was observed.
Intrathecal chemotherapy administered via an Ommaya reservoir was incorporated as a method of preventing or treating leptomeningeal dissemination, and appears to be beneficial for patients who receive focal irradiation only. A meta-analysis by Athale et al. [19] showed that intrathecal therapy also made a significant difference in OS (10.5 months vs. 6.5 months, \( P = 0.011 \)). Intrathecal therapy in the MUV-ATRT-treated patients consisted originally of alternating courses of methotrexate and mafosfamide. When mafosfamide was no longer available, treatment was switched to alternating courses of methotrexate, etoposide, and liposomal cytarabine. Given the good penetrance of systemic methotrexate into the CSF and the potentially increased risk for leukoencephalopathy with additional intrathecal methotrexate, intrathecal methotrexate was omitted in the last three patients of the series.

The role of HDCT in ATRT remains unclear and no definitive conclusions can be made from published data. However, for patients who do not receive radiotherapy HDCT may prevent or delay recurrence as indicated by the results of the “Head Start II” [35] protocol. Furthermore, Finkelstein-Shechter et al. [32] reported on six patients with ATRT who received induction therapy followed by sequential HDCT with autologous stem cell rescue. At a median follow-up of 52 months, four patients were alive without evidence of tumor and three of these patients, including two with metastatic disease were not irradiated. Nicolaides et al. [36] reported on a series of nine consecutive patients with ATRT treated with HDCT and autologous bone marrow transplant and one of the two long-term survivors (98 months from diagnosis) was not irradiated. Similarly, six out of 11 long-term survivors of a Canadian national retrospective study were treated with HDCT without irradiation (median follow-up 38.1 months) suggesting that some patients with ATRT may be spared from radiation [15]. In our series, case 9 of cohort B, originally misdiagnosed as CNS PNET, received HDCT as consolidation immediately after HIT SKK 92, albeit no irradiation. She recurred with a combined local and leptomeningeal relapse 46 months after diagnosis.

In conclusion, the OS and EFS rates of our patients provide the best results achieved in patients with ATRTs so far. An initial correct diagnosis, quick start of therapy, adherence to the sequence and dosing of the regimen as well as strict avoidance of delays in therapy appear to be efficacious in preventing early relapses also in young children with M1–M3 stage disease allowing postponement of radiotherapy until after HDCT. Further studies are warranted to confirm the results in a larger cohort of patients and evaluate whether local radiotherapy may be omitted in selected cases.

Acknowledgments

We thank Karl Roessler for providing clinical information and tumor of a patient transferred for therapy. This study was supported by the “Forschungsgesellschaft fuer cerebrale Tumore.”

Conflict of Interest

None declared.

References

1. Wochrer, A., I. Slavc, T. Waldhoer, H. Heinzl, N. Zielonke, T. Czech, et al. 2010. Incidence of atypical teratoid/rhabdoid tumors in children: a population-based study by the Austrian Brain Tumor Registry, 1996–2006. Cancer 116:5725–5732.
2. Beckwith, J. B., and N. F. Palmer. 1978. Histopathology and prognosis of Wilms tumors: results from the First National Wilms’ Tumor Study. Cancer 41:1937–1948.
3. Rorke, L. B., R. J. Packer, and J. A. Biegel. 1996. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J. Neurosurg. 85:56–65.
4. Kleihues, P., and W. K. Cavanee. 2000. Pathology and genetics of tumours of the nervous system. 3rd ed. IARC Press, Lyon, France.
5. Bourdeaut, F., D. Lequin, L. Brugieres, S. Reynaud, C. Dufour, F. Doz, et al. 2011. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin. Cancer Res. 17:31–38.
6. Eaton, K. W., L. S. Tooke, L. M. Wainwright, A. R. Judkins, and J. A. Biegel. 2011. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr. Blood Cancer 56:7–15.
7. Judkins, A. R., J. Mauger, A. Ht, L. B. Rorke, and J. A. Biegel. 2004. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am. J. Surg. Pathol. 28:644–650.
8. Haberler, C., U. Laggner, I. Slavc, T. Czech, I. M. Ambros, P. F. Ambros et al. 2006. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am. J. Surg. Pathol. 30:1462–1468.
9. Burger, P. C., I. T. Yu, T. Tihan, H. S. Friedman, D. R. Strother, J. L. Kepner, et al. 1998. Atypical teratoid/ rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am. J. Surg. Pathol. 22:1083–1092.
10. Hilden, J. M., S. Meerbaum, P. Burger, J. Finlay, A. Janss, B. W. Scheithauer, et al. 2004. Central nervous system
11. Tekautz, T. M., C. E. Fuller, S. Blaney, M. Fouladi, A. Broniscer, T. E. Merchant, et al. 2005. Atypical teratoid/rhabdoid tumors (AT/RT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J. Clin. Oncol. 23:1491–1499.

12. Morgenstern, D. A., S. Gibson, T. Brown, N. J. Sebire, and J. Anderson. 2010. Clinical and pathological features of paediatric malignant rhabdoid tumours. Pediatr. Blood Cancer 54:29–34.

13. Buscariolo, D. L., H. S. Park, K. B. Roberts, and J. B. Yu. 2012. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer 118:4212–4219.

14. von Hoff, K., B. Hinkes, E. Dannenmann-Stern, A. O. von Bueren, M. Warmuth-Metz, N. Soerensen, et al. 2011. Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database. Pediatr. Blood Cancer 57:978–985.

15. Lafay-Cousin, L., C. Hawkins, A. S. Carret, D. Johnston, S. Zelecer, B. Wilson, et al. 2012. Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. Eur. J. Cancer 48:353–359.

16. Ginn, K. F., and A. Gajjar. 2012. Atypical teratoid rhabdoid tumor: current therapy and future directions. Front. Oncol. 2:114.

17. Zimmerman, M. A., L. C. Goumerova, M. Proctor, R. M. Scott, K. Marcus, S. L. Pomeroy, et al. 2005. Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J. Neurooncol. 72:77–84.

18. Chi, S. N., M. A. Zimmerman, X. Yao, K. J. Cohen, P. Burger, J. A. Biegel, et al. 2009. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J. Clin. Oncol. 27: 385–389.

19. Athale, U. H., J. Duckworth, I. Odame, and R. Barr. 2009. Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J. Pediatr. Hematol. Oncol. 31:651–663.

20. Czech, T., A. Reinprecht, W. Dietrich, I. Hainfellner, and I. Slavc. 1997. Reversible occlusion shunt for intraventricular chemotherapy in shunt-dependent brain tumor patients. Pediatr. Hematol. Oncol. 14:375–380.

21. Louis, D. N., H. Ohgaki, D. Wiestler, W. K. Cavenee, P. C. Burger, A. Jouvet, et al. 2007. WHO classification of tumours of the central nervous system. IARC Press, Lyon, France.

22. Dunkel, I. J., and J. L. Finlay. 2002. High-dose chemotherapy with autologous stem cell rescue for brain tumors. Crit. Rev. Oncol. Hematol. 41:197–204.

23. Rutkowski, S., U. Bode, F. Deinlein, H. Ottensmeier, M. Warmuth-Metz, N. Soerensen, et al. 2005. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med. 352:978–986.

24. von Hoff, K., B. Hinkes, N. U. Gerber, F. Deinlein, U. Mittler, C. Urban, et al. 2009. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT’91. Eur. J. Cancer 45:1209–1217.

25. Slavc, I., E. Schuller, J. Falger, M. Guntes, K. Pillwein, T. Czech, et al. 2003. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J. Neurooncol. 64:239–247.

26. Peyrl, A., M. Chocholous, M. W. Kieran, A. A. Azizi, C. Prucker, T. Czech, et al. 2012. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr. Blood Cancer 59:511–517.

27. Macdonald, D. R., T. L. Cascino, S. C. Schold, Jr., and J. G. Cairncross. 1990. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8:1277–1280.

28. Lanvers-Kaminsky, C., B. Krefeld, A. G. Dinnesen, D. Deuster, E. Seifert, G. Wurthwein, et al. 2006. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr. Blood Cancer 47:183–193.

29. Pai Panandiker, A. S., T. E. Merchant, C. Beltran, S. Wu, S. Sharma, F. A. Boop, et al. 2012. Sequencing of local therapy affects the pattern of treatment failure and survival in children with atypical teratoid rhabdoid tumors of the central nervous system. Int. J. Radiat. Oncol. Biol. Phys. 82:1756–1763.

30. Squire, S. E., M. D. Chan, and K. J. Marcus. 2007. Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy. J. Neurooncol. 81:97–111.

31. Duffner, P. K., and M. E. Cohen. 1991. Long-term consequences of CNS treatment for childhood cancer: Part II. Clinical consequences. Pediatr. Neurol. 7:237–242.

32. Finkelstein-Shechter, T., A. Gassas, D. Mabbott, A. Huang, U. Bartels, U. Tabori, et al. 2010. Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy. J. Pediatr. Hematol. Oncol. 32:e182–e186.

33. Hasan, A., M. Palumbo, J. Atkinson, A. S. Carret, J. P. Farmer, J. Montes, et al. 2011. Treatment-related morbidity in atypical teratoid/rhabdoid tumor: multifocal necrotizing leukoencephalopathy. Pediatr. Neurosurg. 47:7–14.
34. Fidani, P., M. A. De Ioris, A. Serra, L. De Sio, I. Ilari, R. Cozza, et al. 2009. A multimodal strategy based on surgery, radiotherapy, ICE regimen and high dose chemotherapy in atypical teratoid/rhabdoid tumours: a single institution experience. J. Neurooncol. 92:177–183.
35. Gardner, S. L., S. Asgharzadeh, A. Green, B. Horn, G. McCowage, and J. Finlay. 2008. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr. Blood Cancer 51:235–240.
36. Nicolaides, T., T. Tihan, B. Horn, J. Biegel, M. Prados, and A. Banerjee. 2010. High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system. J. Neurooncol. 98:117–123.